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ABSTRACT
Background: DNA methylation patterns are often changed in cancer cells. Many 
of the tumor inhibitor genes are silenced by methylation, such as CDKN2B, p73, 
and the suppressor of cytokine signaling in patients with acute myeloblastic 
leukemia (AML). Secreted frizzled-related protein -4 and -5 (SFRP4, 5) are 
negative regulators of the Wnt signaling pathway. We aimed to evaluate the 
methylation status of SFRP4 and SFRP5 genes in patients with AML.
Methods: Blood samples were isolated from 60 patients with AML and 30 
healthy controls. DNA was exploited, treated with sodium bisulfite, and tested 
utilizing methylation-specific polymerase chain reaction with specific primers 
for methylated and unmethylated sequences of the SFRP4 and SFRP5 genes.
Results: The frequency of unfit hypermethylation of SFRP4 and SFRP5 genes 
in patients with AML was characterized to be 50% (30/60) and 40% (24/60), 
respectively. Moreover, for all the subjects in the control group, methylation of 
SFRP4 and SFRP5 genes was negative. The spread of SFRP4 and SFRP5 promoter 
methylation in patients with AML was higher than the control population.
Conclusion: Hypermethylation was seen in SFRP4 and SFRP5 genes in patients 
with AML. 
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Introduction 
Acute myeloblastic leukemia (AML) is a heterogeneous 
group of hematological malignancies characterized by 
uncontrolled self-renewal of hematopoietic stem cells, 
maturation arrest at myeloblast level, peripheral blood 
and bone marrow infiltration of blast cells.1 Progress 
in molecular studies has improved our understanding 
of leukemogenesis in AML. In addition to age, white 
blood cells count and cytogenetic aberrations; molecular 
genetic modifications affecting nucleophosmin-1 (NPM1), 
FLT3 genes and wilms tumor (WT1) are identified as 
important prognostic factors in patients with AML.2 
DNA methylation is the most important epigenetic 
marker which involves the addition of the methyl group 
to the cytosine residue of CpG (CpG Island) located 
within the promoter region of gene-regulating cell 
proliferation, apoptosis, and DNA repair.3 Improper 
promoter methylation leading to functional inactivation of 
tumor suppressor genes is a well-recognized mechanism 
capable of driving carcinogenesis.4 In AML, many tumor 
suppressor genes are silenced by DNA methylation, 
such as CDKN2B, P73, and suppressor of cytokine 
signaling. Epigenetic disturbances, in contrast to genetic 
modifications are reversible and hence, the role of DNA 
demethylating agents such as azacitidine and decitabine 
in treating hematopoietic malignancies will be more 
attractive.5 In recent years, epigenetic modifications, as 
well as methylation of tumor suppressor genes such as 
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the SFRP family genes have a role in the pathogenesis 
of AML.1, 6 SFRPs are the extracellular antagonists of 
Wnt signaling that sequester Wnt molecules at the cell 
surface membrane7 and by this are recognized as sensitive 
regulators of the canonical Wnt signaling pathway.8 The 
signaling pathway of Wnt contributes to the regulation of 
cell differentiation and proliferation.9 In normal cells, Wnt 
signaling and β-catenin localization are tightly controlled 
by a number of intracellular secreted inhibitory proteins, 
including Dickkopf -1, -2 (DKK-1, -2), serine/ threonine 
kinase-11 (LKB1), Ras association domain-containing 
protein 1, runt-related transcription factor 3 (RUNX3), 
(SFRP-1, -2, -4, -5), SRY-box containing gene 17 (SOX17), 
and WNT inhibitory factor 1 (WIF1).10-12 Aberrant 
activation of Wnt/β-catenin signaling is thought to be 
involved in tumorigenesis.13 Considering the aberrant 
promoter methylation of these genes in leukemogenesis, 
we aimed to study the methylation status of SFRP-4 and 
SFRP-5 genes among de novo patients with AML.
Materials and Methods 
After obtaining written informed consent, blood samples 
were taken from 60 patients with AML at diagnosis and 
30 healthy controls. The patients were divided according 
to FAB (French-American-British) classification system. 
The clinical and laboratory parameters including age, 
CBC, complete remission, death, and relapse were elicited 
from patients’ medical records. 
Mononuclear cells of isolated samples including 
leukemic blast cells were separated by concentration 
gradient sedimentation applying Ficoll-hypaque, 
subsequently DNA was extracted using a saturated salt 
standard procedure.12 In the next phase, exploited DNA 
experienced bisulfite conversion using Epitect Bisulfite 
Kits (Qiagen). By this treatment, unmethylated cytosine 
was transformed to uracil while methylated cytosine 
remained intact. The methylation situation of SFRP-4 
and SFRP-5 genes was studied using Methylation-specific 
polymerase chain reaction (MSP-PCR). MSP is a kind of 
PCR applied to investigate the methylation state of the 
CpG islands. In this method, two pairs of primers specified 
for checking the methylated or unmethylated residues 
are utilized. The methylated SFRP4–specific primers 
forward, 5’-AGTTTACGTTAGGGGAGGTGTC-3’ 
and reverse, 5’- CTCCAATCGACAACAAAACG-3’ 
as well as the unmethylated SFRP4–specific primers 
forward, 5’-GAGTTTATGTTAGGGGAGGTGTT-3’ and 
reverse, 5’- AAACTCCAATCAACAACAAAACAA-3’ 
were used. SFRP5 MSP primers were as follow: 
unmethylated (U) allele-specific primers (F) 5’- 
TGGTGTTGGGTGGGATGTTTG-3’ and (R) 
5’- CAACCCAAACCTCACCATACAC-3, and 
methylated (M) allele-specific primers (F) 5’- 
TGGCGTTGGGCGGGACGTTC-3’ and (R) 5’- 
AACCCGAACCTCGCCGTACG-3’. In methylation 
examination, we used 2 μl of DNA which previously 
had been treated with Bisulfite, 4 μl of dH20, 12 μl of 
master mix, 0.5 μl of a forward primer and 0.5 μl of 
reverse primer while in order to survey the unmethylated 
status, we used 2 μl of DNA, 7.5 μl of dH20, 12 μl of 
master mix, 0.5 μl of forwarding primer, 0.5 μl of reverse 
primer and 0.5 μl of MgCl2. At the first level of MSP, 
reaction components were put in pre-thermal condition, 
including 96 ºC for 1 minute and 95 ºC for 3 minutes, 
followed by 30 cycles, including 96 ºC for 10 seconds, 95 
ºC for 60 seconds, 58 ºC for 30 seconds (unmethylated 
Primers), 60 ºC for 30 seconds (methylated Primers) and 
72 ºC for 3 minutes (extension). In the current study, 
we used the EpiTect PCR control DNA kit (Qiagen) 
containing unmethylated and thoroughly methylated 
DNAs as negative and positive controls, respectively. 
Electrophoresis on the 2.5 ℅ Agarose gel was performed 
for MSP product recognition (figure 1). 
Fisher’s exact two-sided test, Mann–Whitney U-test and 
SPSS analytic software (version 21, SPSS Inc, Chicago, 
IL) were utilized for statistical analysis of the data. P<0.05 
was considered statistically significant. 
Results
There were 43 (71.7℅) men and 17 (28.3℅) women in 
the studied AML patients (age range: 45-69 years). 
SFRP4 gene was found to be hemi-methylated, entirely 
methylated and completely unmethylated in 18 (30℅), 12 
(20℅), and 30 (50℅) patients; whereas SFRP5 gene was 
hemi-methylated, completely methylated and thoroughly 
unmethylated in 16 (26.7℅), 8 (13.3℅) and 36 (60℅) 
patients (figure 1). None of the participants in the control 
group had methylation in SFRP4 and SFRP5 genes. The 
number of patients with hypermethylation of SFRP4 and 
SFRP5 genes were 20℅ and 13.3℅, respectively. Also, 
18.4 ℅of the patients (11 out of 60) showed methylated 
SFRP4 and SFRP5 genes at the time of diagnosis (table 1). 
Improper methylation of these genes was found in all FAB 
subtypes of AML. There was no association between 
hypermethylation status of SFRP4 and SFRP5 genes 
with FAB subtypes of AML and clinical and laboratory 
Figure 1: MSP analysis of SFRP4 and SFRP5 genes in AML patients and normal control. dH2O served as a blank control. PC: 
Positive control; NC: Negative control; P: Patient; M: Methylated; U: Unmethylated. 
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parameters including age, sex, WBC and platelet count 
(table 1). 11 out of 60 patients developed relapse, of which 
5 patients showed SFRP4 and 4 patients displayed SFRP5 
gene hypermethylation.
There was no correlation between hypermethylation 
in SFRP-4 and -5 genes and relapse (P=0.739 and 
P=0.160, respectively). 46 (76.7 %) patients achieved 
remission after induction chemotherapy. Among 
patients with complete remission, 21 (70 %) and 22 
(91.6 %) patients were hypermethylated in the SFRP4 
and SFRP5 genes, respectively (P=0.784, P=0.910). 3 
(5%) patients did not achieve remission, of these 1 and 2 
patients had hypermethylation in the SFRP4 and SFRP5 
genes, respectively. There was no association between 
hypermethylation of SFRP4 and SFRP5 genes and 
remission status after induction chemotherapy. 
Discussion
Epigenetic alterations, such as DNA methylation have 
emerged as additional and equally important mechanisms 
besides genetic alterations.14 Understanding the 
developing role of the Wnt pathway in the permanence, 
multiplication, and differentiation of hematopoietic 
stem cells have led to the different hypotheses that this 
signaling pathway may be involved in leukemogenesis.15 
This critical developmental pathway is dysregulated in 
several human tumors including breast cancer,16 acute 
leukemia,17 human hepatocellular carcinoma18 and B-cell 
chronic lymphocytic leukemia.14 Aberrant promoter 
methylation leading to the inactivation of tumor suppressor 
genes is a well-known mechanism capable of driving 
carcinogenesis.19 Wnt/β-catenin signaling pathway has 
been involved in a large number of pathways such as cell 
proliferation, cell morphology, destiny designation of 
cells and organ development.18 SFRP-4 and -5 are tumor 
suppressor proteins that modulate the Wnt/ β-catenin 
signaling pathway. These proteins bind to Wnt protein 
and consequently prevent its binding to the Wnt-receptor.
In the present study, we investigated the methylation 
status of SFRP4 and SFRP5 genes in newly diagnosed 
patients with AML. The results of this study showed 
hypermethylation of SFRP4 and SFRP5 genes in 30% and 
24% of AML patients, respectively. None of the subjects 
in the control group revealed any methylation. Wnt 
signaling activates pathways that play an important role 
in proliferation and differentiation.20 Hypermethylation 
of Wnt signaling pathway inhibitors such as SFRP-1, 
SFRP-2,1 Wnt inhibitory factor 1 (WIF1) and dickkopf-1 
(DKK-1)21 genes has also been shown in AML. Therefore, 
methylation of these genes may be involved in the initiation 
of AML and it may also have a role in its pathogenesis 
by dysregulation of the WNT signaling pathway. Yu and 
colleagues demonstrated that SFRP gene methylation may 
be involved in acute leukemia progression, with a possible 
epigenetic mechanism influencing Wnt signaling.17 Simon 
et al. have recommended that recombinant SFRP might 
be a new treatment strategy for cancers with suppressed 
SFRP expression.22 Epigenetic changes, in contrast to 
genetic modifications, are reversible and the role of 
DNA demethylating agents such as AZA and 5-aza-2´-
deoxycytidine has been recognized in the treatment of 
hematopoietic disorders.5, 23 The percentage of patients 
with an aberrant methylation of at least one SFRP4 or 
SFRP5 gene in this study was 20% for SFRP4 and 13.3% 
for SFRP5. silencing of SFRPs by CpG island methylation 
is another possible mechanism contributing to the aberrant 
activation of the Wnt signaling pathway in CLL suggested 
by Liu et al.14 The frequency of hypermethylation of 
SFRP4 or SFRP5 genes in our study was lower than 
those reported by Griffiths et al.24 and higher than those 
reported by Jian-Zhen Shen et al. (6.8% and 11.9%, 
respectively; total: 18.7%).17 This is probably due to the 
differences in patient selection and ethnic diversity. Our 
results showed that aberrant methylation of these genes 
Table 1: Association between methylation of SFRP4 and SFRP5 genes and clinical indications of AML patients.
Characteristics SFRP4 SFRP5
M U P M U P
Number of Patients, (%) 30 (50) 30 (50) 24 (40) 36 (60)
Age, median26years 59.1 (51-69) 56.8 (49-64) 0.247 54.3 (45-66) 53 (51-62) 0.513
Sex, % 0.567 0.773
Male 23 20 18 25
Female 7 10 6 11
WBC count (mm3), mean±SD 31716±7312 26587±3563 0.203 35137±8109 30155±5579 0.424
Platelet count (mm3), mean±SD 221706±17534 236321±10345 0.521 1964743±20321 2086071±10211 0.317
Hb g/dL, mean±SD 15.6±1.5 15.3±1.3 0.399 14.9±1.8 15.5±2.1 0.386
FAB type, n (%)
M0/M1 2 (6.7) 1 (3.3) 0.554 1 (4.1) 2 (5.5) 0.809
M2 11 (36.6) 13 (43.4) 0.598 12 (50) 14 (38.9) 0.395
M4 8 (26.7) 10 (33.3) 0.573 6 (25) 10 (27.8) 0.812
M5 7 (23.3) 6 (20) 0.754 4 (16.8) 9 (25) 0.443
M6 2 (6.7) 0 0.150 1 (4.1) 1 (2.8) 0.801
Outcome, n (%)
Complete remission 21 (70) 25 (83.4) 0.784 22 (91.6) 24 (66.6) 0.910
Death 3 (10) 2 (6.6) 0.640 2 (8.3) 3 (8.3) 0.333
Relapse 5 (16.6) 6 (20) 0.739 4 (16.6) 2 (5.5) 0.160
AML: AML, Hb: hemoglobin, WBC: white blood cell, FAB: French-American-British, M: methylated, U: unmethylated.
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were observed in all FAB subtypes (M0 through M6). 
Hou et al. pointed out that DKK-1 hypermethylation 
frequently occurs concomitantly with hypermethylation 
of the SFRP family, but not Wif-1.25
In this study, we did not observe any significant 
association between hypermethylation of these genes and 
clinical, laboratory or conventional prognostic factors 
in AML such as age and sex, WBC, platelet count or 
hemoglobin.
Conclusion 
The present study showed that hypermethylation in 
SFRP-4 and -5 genes occurs in AML similar to solid 
tumors. Assessment of other antagonists of Wnt signaling 
pathways are recommended to further explore the status 
of DNA methylation, cell differentiation and proliferation 
in different kinds of malignancies.
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